Efficacy and safety of insulin degludec in Japanese type 2 diabetes

Efficacy and safety of insulin degludec in Japanese type 2 diabetes - Efficacy and safety of insulin degludec in Japanese type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011550

Enrollment

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Insulin glargine is replaced to insulin degludec with same dose. The dose of insulin degludec is adjusted every 2 weeks. CGM is performed before and 6 weeks after replacement.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with type 2 diabetes,who are on insulin glargine therapy (2)HbA1c >7.0% (3)written informed consent

Exclusion criteria

Exclusion criteria: (1)severe ketosis, diabetic coma (2)history of severe hypoglycemia (3)severe renal dysfunction (eGFR <30) and hepatic dysfunction (4)pancreatic deasease, endocrine deasease, taking diabetogenic medication (5)pregnancy (6)unable to self-injection (7)allergy for degludec or glargine (8)judged as ineligible by clinical investigators for some other reasons

Design outcomes

Primary

Measure	Time frame
glucose variability by Continuous Glucose Monitoring System	—

Secondary

Measure	Time frame
Frequency of hypoglycemia, Blood glucose plofile measured by SMBG, HbA1c, 1,5-AG, insulin dose	—

Countries

Japan

Contacts

Public ContactNaoki Kuramoto

Kansai Electric Power Hospital Center for Diabetes, Metabolism and Endocrinology

naoki.kuramoto@c5.kepco.co.jp06-6458-5821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026